शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEDeccan Health Care Limited· Healthcare ServicesHighNeutral
Announced Fri, 14 Aug, 2026 · 14:09 IST

Deccan Health Care Q1FY27 Results: PAT Rs 24.63 lakh, Revenue Rs 21.86 cr

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.3%Reaction day
₹13.52
prior close
₹13.39
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.3% vs market
Healthcare Service Provider peers, median of 26sector-2.0%-3.3% vs sector

On the reaction day the stock moved 5.3 pts less than Nifty Microcap 250 and 3.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
+0.0
30m
-4.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.3+0.1-5.3-2.0-3.3
Next day
-8.0+0.2-8.2-0.3-7.7
2d
-4.3+0.6-4.9-0.3-4.0
3d
-3.9-0.0-3.9-3.7-0.2
4d
-0.2+0.5-0.7-3.6+3.3
5d
-0.1+0.8-0.9-2.9+2.7
1w
-3.0+0.6-3.5-0.2-2.7
15d
-5.8+1.3-7.1+1.7-7.5
1m
-6.1-1.4-4.8+0.1-6.3
2m
-5.2-0.6-4.6-5.8+0.6
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Deccan Health Care posted Q1FY27 standalone revenue of Rs 21.86 cr vs Rs 21.47 cr YoY, up about 1.8%. PAT rose 15.9% to Rs 24.63 lakh from Rs 21.25 lakh. EPS stood at Rs 0.10 vs Rs 0.09. Cost of materials spiked 18% to Rs 22.47 cr. On consolidated basis, revenue was Rs 22.07 cr with PAT of Rs 29.11 lakh (up 22.8% YoY). Subsidiary Beyoungstore added Rs 4.50 lakh PAT. Auditor issued an unmodified limited review report. No investor complaints pending.

Likely market impact

Flat top line but healthy PAT growth on cost control. Clean audit report. No strong near-term catalyst visible.